We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clarifies Term ‘Outsourcing Facility,’ Requirements for 503A Compounders
FDA Clarifies Term ‘Outsourcing Facility,’ Requirements for 503A Compounders
As part of its increased focus on drug compounding, the FDA issued a final guidance clarifying the term “outsourcing facility” and detailing requirements for compounders operating under 503A that are next to an outsourcing facility.